Researchers reported preclinical activity for an IL-6-responsive engineered CAR macrophage construct combined with CAR-T cells in solid tumor models. The approach uses an IL-6-binding module to trigger a matrix-remodeling program, with combined therapy increasing tumor killing and prolonging survival in mice. The study’s mechanistic emphasis is on converting a potentially immunosuppressive IL-6 microenvironment signal into extracellular matrix degradation to improve immune cell infiltration. The construct’s activity was shown to be specific to CD147 signaling and dependent on the IL-6 trigger in preclinical assays. Because the results remain limited to preclinical cell and animal data, translation hurdles—long-term safety, dosing, and validated control of inflammatory signals—will determine whether this strategy advances toward clinical testing.